Palvella Therapeutics, Inc. (PVLA) - What Are Brokerages Saying About This Stock?

Key Points

• Analyst sentiment is broadly positive: 15 analysts give Palvella Therapeutics an average “Buy” rating, with a mean 12-month price target of $213.85. Recent targets include $232 from Oppenheimer and $240 from Chardan Capital.
• Palvella reported quarterly earnings per share of -$1.70, beating the consensus estimate of -$1.78 by $0.08. Shares were recently trading at $152.48.
• Company insiders sold 67,306 shares worth about $9.8 million over the past 90 days, while hedge funds and other institutional investors own 40.11% of the stock.

Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) has been given an average rating of "Buy" by the fifteen analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $213.85.

Several analysts recently weighed in on PVLA shares. Oppenheimer upped their price target on Palvella Therapeutics from $210.00 to $232.00 and gave the stock an "outperform" rating in a research note on Friday, November 6th. Chardan Capital reaffirmed a "buy" rating and issued a $240.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, October 28th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Palvella Therapeutics in a research note on Friday, September 25th. Raymond James Financial set a $226.00 price objective on shares of Palvella Therapeutics in a research report on Friday, October 16th. Finally, HC Wainwright initiated coverage on shares of Palvella Therapeutics in a research note on Friday, November 6th. They set a "strong-buy" rating for the company.

Palvella Therapeutics Price Performance

Palvella Therapeutics stock traded down $0.70 during trading hours on Friday, reaching $152.48. The stock had a trading volume of 240,297 shares, compared to its average volume of 281,191. The stock has a market cap of $2.23 billion, a PE ratio of -27.72 and a beta of -0.21. Palvella Therapeutics has a 52 week low of $72.22 and a 52 week high of $179.95. The company has a fifty day simple moving average of $143.56 and a 200-day simple moving average of $129.97.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($1.70) earnings per share for the quarter, topping the consensus estimate of ($1.78) by $0.08. Research analysts predict that Palvella Therapeutics will post -6.29 earnings per share for the current fiscal year.

Insider Activity at Palvella Therapeutics

In related news, Director Christopher Kiritsy sold 313 shares of Palvella Therapeutics stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total value of $49,141.00. Following the completion of the sale, the director owned 250 shares of the company's stock, valued at $39,250. The trade was a 55.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director George Jenkins sold 7,174 shares of the company's stock in a transaction dated Tuesday, October 13th. The shares were sold at an average price of $130.36, for a total transaction of $935,202.64. Following the sale, the director directly owned 139,790 shares of the company's stock, valued at $18,223,024.40. The trade was a 4.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 67,306 shares of company stock worth $9,800,571. 17.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Palvella Therapeutics

Several institutional investors have recently bought and sold shares of PVLA. BlackRock Inc. purchased a new stake in shares of Palvella Therapeutics during the 2nd quarter valued at $140,343,000. Marshall Wace LLP raised its position in shares of Palvella Therapeutics by 11,463.8% in the 3rd quarter. Marshall Wace LLP now owns 329,799 shares of the company's stock valued at $45,489,000 after purchasing an additional 326,947 shares during the last quarter. First Light Asset Management LLC boosted its stake in Palvella Therapeutics by 38.3% in the 1st quarter. First Light Asset Management LLC now owns 980,758 shares of the company's stock worth $122,251,000 after purchasing an additional 271,617 shares in the last quarter. Primecap Management Co. CA acquired a new stake in Palvella Therapeutics in the 2nd quarter worth approximately $39,150,000. Finally, Jennison Associates LLC boosted its stake in Palvella Therapeutics by 65.3% in the 1st quarter. Jennison Associates LLC now owns 640,611 shares of the company's stock worth $79,852,000 after purchasing an additional 253,128 shares in the last quarter. 40.11% of the stock is owned by hedge funds and other institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania. Its pipeline includes QTORIN-based topical drug candidates, which use the company's platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.